Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

NCT07643519 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma (UC)

Interventions

DRUG: enfortumab vedotin and pembrolizumab (EV/P)

Sponsor

University of Florida